Clinigen Group opens Global Operations Centre

Published: 14-Mar-2012
Pharmaceutical

Will improve distribution and stock levels

Clinigen Group, a global specialist pharmaceutical products and services business based in the UK, has opened a new £350,000 Global Operations Centre in Stretton, near Burton-on-Trent Staffordshire.

Peter George, chief executive of Clinigen, said: ‘We are continuing to expand and have ambitious plans for the future. It is essential that we have the right resource and facilities to service our clients, both now, and as we continue to develop.’

The firm says the new 8,000ft2 warehousing and distribution facilities will enable it to stock and distribute pharmaceutical products to its global customer base in a fast and efficient manner.

The new Operations Centre combined with the company's headquarters in Burton, have created more than 30 new jobs in recent months. In total the firm employs 300 staff.

Clinigen Group was formed in 2010 by the merger of three companies: Clinigen CTS (formerly Keats Healthcare) and Clinigen GAP, which make up Clinigen's services division, and Clinigen Healthcare, the Group's products business.

The Group operates across the clinical lifecycle of a drug, from Phase 1 clinical trials to the end of patent and beyond.

See more

You may also like

Distribution

Santhera and Clinigen partner to distribute DMD treatment AGAMREE to eligible patients globally

Read more
Clinigen Group will be respsonsible for the distribution of Duchenne muscular dystrophy (DMD) treatment AGAMREE (vamorolone) in regions not currently covered by Santhera or its distribution partners

Trending Articles

  1. dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
  2. Tekpak Automation to showcase pharma pick-and-place robotic cell at interpack 2026 Tekpak Automation will demonstrate the benefits of robotics for pharmaceutical applications at interpack 2026, with a LIVE working demonstration of a 3-axis pick-and-place cell handling medipens on Stand A15/Hall 16
  3. FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
  4. FDA warns of drug-induced liver injury risk with Amgen's Tavneos after deaths The US Food and Drug Administration has issued a safety warning linking Amgen's vasculitis drug Tavneos to 76 cases of drug-induced liver injury globally, including eight deaths and seven cases of vanishing bile duct syndrome, recommending comprehensive liver monitoring during the first five months of treatment
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Semaglutide patent cliff: pharma industry braces for impact With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

You may also like

Distribution

Santhera and Clinigen partner to distribute DMD treatment AGAMREE to eligible patients globally

Clinigen Group will be respsonsible for the distribution of Duchenne muscular dystrophy (DMD) treatment AGAMREE (vamorolone) in regions not currently covered by Santhera or its distribution partners
Packaging

Packaging for success

Somewhat misguidedly, pharmaceutical packaging is often overlooked or assumed to be a commodity service that “anyone can do,” says Scott Houlton, CEO, CSM (a Clinigen Group company)
Finance

Clinigen’s £225m acquisition of Idis goes ahead

Acquisition accelerates the company's growth, provides a better balanced portfolio and extends its business model
Finance

2014 Sunday Times Rich List sees entry of more pharma executives

Ernesto and Kirsty Bertarelli are still out ahead of the rest
Manufacturing

Touchlight partners with SVF Vaccines to advance dual hepatitis B/D vaccine into clinical development

The pair will progress an innovative dual-targeting hepatitis B and D vaccine into clinical trials, leveraging Touchlight's enzymatic doggybone DNA platform, which has demonstrated significant dose-sparing potential compared to traditional plasmid DNA
Pharmaceutical

From complexity to confidence: Smurfit Westrock finds a better way to ensure accuracy with EyeC

Demands for printing perfection and regulatory compliance, Smurfit Westrock faced growing complications in producing multilingual pharmaceutical inserts
Research & Development

Oxford BioTherapeutics signs T-cell engager collaboration with Bristol Myers Squibb for solid tumour targets

The company has entered a multi-year collaboration with BMS to discover and develop next-generation T-cell engager therapies for solid tumours using its OGAP-Verify platform, marking the company's third major pharma partnership in twelve months following deals with GSK and Roche
Subscribe now